Treatment of pulmonary exacerbations in cystic fibrosis by Ng, Christabella et al.
   
 
   
 
Current opinion in pulmonary medicine – 
Treatment of pulmonary exacerbations in 
cystic fibrosis 
Ng C*1, Nadig T*2, Smyth AR1, Flume PA2 
*Joint first authors 
1 Division of Child Health, Obstetrics and Gynaecology, University of Nottingham, UK 
2 Department of Medicine, Medical University of South Carolina, US 
 
Corresponding author: Patrick Flume  
  
   
 
   
 
Structured abstract 
Purpose of review:  
This review will discuss the challenges of defining a pulmonary exacerbations in cystic fibrosis (CF) 
and the key pathogens which contribute. It will discuss the treatment options currently available and 
the importance of preventing pulmonary exacerbations.  
Recent findings:  
The basis for treatment of pulmonary exacerbations remains unchanged over the past 15 years and 
whilst there have been trials exploring alternative antibiotics, there has been little change.  
However, there are ongoing studies that are expected to establish a platform for identifying best 
practices.  Chronic CF therapies have been shown to reduce pulmonary exacerbations. In the era of 
new CFTR (CF transmembrane conductance regulator) modulator therapies, the number of 
pulmonary exacerbations are expected to be even fewer. However, it is unclear whether the other 
chronic therapies can be discontinued without losing their benefits in reducing exacerbations.  
Summary:  
Although there is no universal definition of a pulmonary exacerbation in CF, proposed definitions 
have many similarities. We have outlined the current recommendations for treatment of pulmonary 
exacerbations, including the duration and location of treatments. We have also summarised the key 
therapies used for prevention of pulmonary exacerbations in CF.  
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1 Introduction 
Pulmonary exacerbations are common events and contribute to progression of airways disease and 
considerable morbidity in patients with cystic fibrosis (CF).[1] Many events lead to treatment with 
intravenous antibiotics, which are costly and associated with a reduced quality of life. This review 
will focus on the prevention of pulmonary exacerbations in CF and current recommendations for 
their management.    
2 Defining a pulmonary exacerbation 
The CF Foundation defines a pulmonary exacerbation as an “acute worsening of respiratory 
symptoms” requiring medical treatment.[2] Extra-pulmonary symptoms, such as weight loss, are 
commonly seen and there are important differences in presentation between adults and children 
with CF. Although there is a lack of universal agreement on a pulmonary exacerbation definition, 
there is a broad consensus on the type of respiratory signs and symptoms to be included (Table 1); 
none of the definitions have been validated as an instrument for use in clinical research studies.  A 
standardized definition is desirable as it could allow for better comparison of trials and could be 
used in the study of therapies intended to reduce exacerbation frequency.[3]  However, these 
scoring methods assume that all clinicians would come to the same conclusion and ignore the 
clinician’s historical experience with an individual patient, differences that occur with age, and 
psychosocial factors that may influence the decision to treat.  Treatment trials typically take a 
pragmatic approach by not questioning the clinician’s diagnosis.  
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The primary aims of pulmonary exacerbation treatment reported by patients and clinicians are to 
relieve symptoms and recover loss of lung function, respectively.[10] 
4.1 Antibiotics 
4.1.1 Anti-bacterials 
A key feature of CF airways disease is persistent infection and exaggerated inflammation. Given the 
symptoms typically associated with exacerbations (i.e. cough and sputum production), infection is 
often invoked as a likely cause or contributor to the condition, and antibiotics are recommended as 
part of the disease management. Many bacterial species have been identified as potential 
contributors, including Staphylococcus aureus, Hemophilus influenzae, Pseudomonas aeruginosa, 
and Burkholderia complex.[11] S. aureus is the most commonly isolated pathogen in CF, with the 
highest prevalence in children; P. aeruginosa is more prevalent in older children and adults.[1] 
Antibiotics are frequently used to treat a pulmonary exacerbation and sputum microbiology is 
typically used to guide antibiotic selection.[2]  Since information from a sputum culture collected at 
the time of intervention will not be available for several days, clinicians often use prior sputum 
culture data and previous experience with the patient to guide initial antibiotic selection.[12]  While 
some pathogens (e.g. S. aureus) are often treated with a single antibiotic, others (e.g. P. aeruginosa 
   
 
   
 
or B. cepacia) are more often treated with a combination of antibiotics. This practice may be driven 
by concerns for antimicrobial resistance, but there is a disconnect between antibiotic susceptibility 
test results and clinical outcomes.[13] Efforts to overcome this discordance have included use of 
antibiotics selected by synergy testing [14] and microbiome analysis to enhance individualised 
antibiotic therapy [15] but these have not been successful..  
 
Since the information provided by sputum culture and susceptibility testing are limited in their value, 
at least for predicting outcomes for CF pulmonary exacerbations, consensus recommendations have 
been provided.[12]  Anti-bacterials should be selected based on bacterial species isolated in previous 
respiratory cultures and on previous treatment outcomes.  Changes to the antibiotics are more often 
guided by clinical response than by susceptibility test results.  
 
4.1.2 Anti-virals 
Viruses are often identified in respiratory samples collected at the time of a pulmonary 
exacerbation, and so viruses are often implicated as a potential cause of the event.  The most 
commonly identified viral pathogen is human rhinovirus but others include respiratory syncytial virus 
(RSV), Influenza types A and B, and parainfluenza.[10, 11] RSV may promote growth of P. aeruginosa 
biofilms through modulation of the immune response and pathogen iron metabolism while 
rhinovirus has been shown to promote the free movement of P. aeruginosa from biofilms. [12, 13] 
All people with CF are advised to receive the annual Influenza vaccine to reduce their risk of a 
pulmonary exacerbation during the flu season. For those patients who have an influenza infection, 
treatment with neuraminidase inhibitors are frequently used, although there are no substantive 
clinical trials to support this treatment.[16]  There are no other specific antiviral therapies beyond 
supportive care. Preliminary data suggest that very few CF patients have had a severe respiratory 
illness during the recent COVID-19 pandemic.[17] 
4.1.3 Anti-fungals 
The role for fungi in the pathogenesis of CF airways disease has long been debated and there are no 
current recommendations to treat fungi isolated in respiratory cultures.  However, there is a greater 
incidence of allergic bronchopulmonary aspergillosis (ABPA) and pulmonary exacerbations in 
patients with CF may be due wholly, or in part, to ABPA. There are no randomised controlled trials 
evaluating the treatment of ABPA in CF, but a combination of systemic corticosteroids and antifungal 
treatment is recommended in treatment guidelines.[18]  
4.2 Duration of treatment  
Optimal duration of intravenous antibiotic therapy is still not established and practices vary 
according to the care site.[1] Durations vary from 4-21 days in paediatric programs to 4-23.5 days in 
adult programs.[1] An observational study of patients admitted to the hospital for treatment of 
pulmonary exacerbations showed a mean duration of intravenous antibiotics were 15.9 days. [3] A 
retrospective study showed improvement in lung function plateaus after 8-10 days of intravenous 
therapy suggesting that shorter durations of antibiotics might be adequate to treat a pulmonary 
exacerbation and the time to next exacerbation was unchanged with this shorter antibiotic 
course.[19]  
There is great importance to determining an optimal duration of antibiotic treatment.  Too short a 
course could result in inadequate treatment leading to recurrence of the exacerbation; indeed 
intravenous antibiotic courses <9 days have been associated with a greater risk of retreatment 
within the next 30 days.[20]  An antibiotic course longer than is necessary is associated with greater 
   
 
   
 
cost and could be associated with a greater risk of complications.  The ongoing Standardized 
Treatment of Pulmonary Exacerbations 2 (STOP2) study is evaluating courses of 10, 14, and 21 days 
of treatment based on initial clinical response and should provide some insight when completed.[10] 
4.3 Location of treatment  
Reports comparing site of therapy, inpatient vs home intravenous therapy, are mainly observational 
and retrospective.  The one randomized trial found no difference in outcomes.[21] More recently, 
analysis of the Epidemiologic Study of Cystic Fibrosis dataset looked at 4500 exacerbations and 
found that inpatient treatment with IV antibiotics was more likely to result in recovery of lung 
function than at-home treatment.[22] Another single centre study of 54 CF patients showed in-
hospital treatment to be superior to home treatment, as indicated by better improvement of FEV1 in 
patients with CF-related complications and weight gain.[23] Conversely, a large (>1500 patients) 
retrospective study comparing inpatient vs at home intravenous antibiotics showed no difference in 
long term FEV1 recovery and time to next exacerbation.[19]  Consequently, there are conflicting data 
as to the ideal site of treatment.  Obviously the assumption must be that the potential for care 
would be similar, but it would be impossible to do a properly conducted study. There are important 
biases in any such study that would be difficult to overcome (e.g. clinician equipoise, subject 
willingness to be randomized]. The guidelines on pulmonary exacerbations recommend that the 
decision should be based on the ability to provide sufficient care as the patient’s clinical status 
should dictate the needs (and therefore may dictate the location) of treatment.  
5 Recovery and sequelae  
Pulmonary exacerbations are associated with loss of lung function (FEV1), decreased survival, and 
worsened quality of life.[3] A cohort study using the CF registry showed that up to 25% of patients 
failed to recover baseline FEV1.[24] A challenge in such analyses is knowledge of what can be defined 
as baseline. In a study using registry data to define baseline (i.e. best lung function in previous 6 
months) the best lung function was at the time of admission in nearly 25% of patients.[3]  
Nonetheless, a more rigorous analysis of the impact of exacerbations on lung function, using a 
baseline defined as the previous lung function measured as part of a clinical trial, found that patients 
returned to baseline lung function only half the time, and this was not improved with a CFTR 
modulator.[25] Multiple factors may contribute to the lack of complete recovery from a pulmonary 
exacerbation, including: aetiology, host response, and treatment. The eICE trial was designed to 
assess whether earlier identification of events could improve outcomes.  Whilst it showed that home 
monitoring of lung function led to identifying more patients with pulmonary exacerbations, the trial 
did not demonstrate a difference in FEV1 after one year of monitoring.[26] However, it could be 
hypothesized that failure to treat with best practices would not be expected to realize such an 
improvement; the exacerbations identified in the home monitoring arm were more likely to receive 
oral antibiotics and less likely to be treated with hospitalisation.  
6 Prevention  
Given the low rate of recovery of lost lung function, then prevention of pulmonary exacerbations 
becomes a much more important strategy. There are some therapies that have demonstrated clear 
benefit while some still lack good evidence. 
Airway Clearance Therapies 
Airway clearance therapies are considered the most basic and essential of CF treatments.  
Augmentation of airway clearance using agents such as dornase alfa, hypertonic saline, and mannitol 
have shown benefits in CF patient by improving mucous clearance.[27] A recent Cochrane systematic 
   
 
   
 
review of dornase alfa for CF confirmed its role in improving lung function and decreasing 
exacerbations. [28] Hypertonic saline (HS) is an osmotic agent that is routinely used and a Cochrane 
systematic review confirmed that use HS reduced frequency of exacerbation but with a limited 
effect on lung function. [29] Guidelines from US, Europe and UK all suggest using dornase alfa as 1st 
choice mucoactive agent for older CF patients. They suggest using dornase alfa and HS in children 
under 5 years on an individual basis but more robust data are required. More recently, mannitol (an 
osmotic agent like HS) has been shown to significantly improve FEV1 and reduce pulmonary 
exacerbations.[30] This effect was initially thought to be applicable for adults only but a subsequent 
study in children between 6-17 years showed similar results.[31] Both HS and mannitol are irritants 
and require pre-treatment with bronchodilator. Direct head to head trials between dornase alfa and 
the other hyperosmolar agents are not sufficiently robust to conclude one’s superiority over the 
other. 
Prophylactic antibiotics  
Macrolide antibiotics like azithromycin have been beneficial to CF patients likely due to their dual 
effect on infection and inflammation. The recent Optimize trial confirmed previous reviews that 
patients treated with azithromycin were less likely to have pulmonary exacerbations.[32, 33] 
Recently, a retrospective cohort study using the CFF patient registry reported a reduction in the 
average rate of annual decline of FEV1 (over 3 years) in patients with P. aeruginosa and receiving 
azithromycin.[34]  
Inhaled antibiotics have proven benefits in CF patients by reducing pulmonary exacerbations and 
improving lung function. [35] While intermittent therapy (28 day on/off) is the labelled regimen,  
continuous daily therapy is increasingly recommended.[18] A study of continuous alternating inhaled 
antibiotic therapy (CAT) for chronic P. aeruginosa infection was halted early because of feasibility 
challenges, leaving the study underpowered; however, the CAT regimen seemed to reduce 
exacerbation rates (by 25%).[36] This approach has become increasingly popular—especially among 
patients with greater impairment in lung function or greater frequency of acute pulmonary 
exacerbations.[1]  
Inhaled glucocorticoids and bronchodilators 
Both inhaled glucocorticoids and bronchodilators (beta‐2 agonists and muscarinic antagonist) are 
used with great frequency as maintenance therapy in CF patients.[1] Recent Cochrane reviews for 
both have shown no significant improvement in lung function and the time until the first 
exacerbation with these interventions.[37, 38]  
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators 
CFTR modulators treat the underlying cause of the disease and have improved clinical outcomes in 
patients with CF. A consistent finding among the various CFTR modulator combinations have 
demonstrated a consistent finding of reduction in pulmonary exacerbations of between 30% and 
63%.[39, 40] [41] Since the impact appears to be greater with the more potent CFTR modulator 
combinations, it is expected that patients treated with them will see a marked improvement in their 
overall health.  However, it is likely that conventional preventative and treatment strategies for 
pulmonary exacerbations will still be needed in the era of CFTR modulators. Trials previously 
evaluating CFTR modulators included chronic therapies and therefore it is unknown whether CFTR 
modulators alone will reduce the number of pulmonary exacerbations. Newer trials such as 
SIMPLIFY, which review stopping some chronic medications, are important research areas.[42] 
   
 
   
 
7 Conclusion 
Acute pulmonary exacerbations in CF are common events and a main cause of morbidity and 
mortality in CF. Although we lack a specific clinical definition for an exacerbation, there are common 
features that have been used in practice.  These events are often associated with acute loss of lung 
function that does not fully recover, and so there is great need to use therapies to prevent 
exacerbations and to determine best practices for treatment of them.  
There are guidelines based upon sound evidence for a number of therapies to reduce the frequency 
of pulmonary exacerbations. A systematic review performed to develop guidance on treatments of 
exacerbations found a paucity of evidence, but there are ongoing studies that should provide greater 
evidence for best practices.[43]   
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